National Comprehensive Cancer Network

About NCCN

NCCN Flash UpdatesTM: NCCN Guidelines® and NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Pancreatic Adenocarcinoma. These NCCN Guidelines® are currently available as Version 1.2015.

  • Neoadjuvant therapy (PANC-3, PANC-4)
    • Footnote “i” has been revised: “There is limited evidence to recommend specific neoadjuvant regimens off-study, and practices vary with regard to the use of chemotherapy and chemoradiation. Acceptable regimens include FOLFIRINOX or gemcitabine + albumin-bound paclitaxel. Subsequent chemoradiation is sometimes included. Most NCCN Member Institutions prefer neoadjuvant therapy at a high-volume center.”
  • Chemoradiation for Locally Advanced Unresectable Disease (PANC-8)
    • Footnote “u” has been revised: “Based on preliminary data from the LAP-07 trial, there is no clear survival benefit with the addition of conventional chemoradiation following gemcitabine monotherapy. Chemoradiation may improve local control and delay the need for resumption therapy. (Huguet F, Hammel P, Vernerey D, et al. Impact of chemoradiation on local control and time without treatment in patients with locally advanced pancreatic cancer included in the international phase III LAP 07 study. J Clin Oncol 2014; 32:5s. Abstract 4001.)”
  • Treatment for Metastatic Disease (PANC-9)
    • Treatment options have been divided into two groups: “Preferred” and “Other Options.”
    • Preferred treatment options include: Clinical trials, or FOLFIRINOX (category 1), or gemcitabine + albumin-bound paclitaxel (category 1).
  • Principles of Diagnosis, Imaging, and Staging (PANC-A)
    • This section has been significantly revised and expanded.
    • Pancreatic adenocarcinoma protocols have been added for the use of multi-detector computed tomography (MDCT) and MRI.
  • Criteria Defining Resectability Status (PANC-B)
    • This section has been significantly revised and put into table format.
  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)
    • A new section discussing premalignant tumors of the pancreas has been added.
    • A new section discussing management of isolated pulmonary metastases has been added.

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium®, please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit

 About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2014 National Comprehensive Cancer Network. All Rights Reserved.

Users may opt-out via e-mail or by updating their profile. Users may unsubscribe at any time by contacting us.

NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.